Advertisement

CEN Case Reports

, Volume 7, Issue 1, pp 98–100 | Cite as

Membranous glomerulonephritis with an LMNA mutation

  • Kumi Fujita
  • Kazuhiro Hatta
Case Report

Abstract

We had encountered the case of membranous glomerulonephritis (MGN) with dilated cardiomyopathy due to LMNA gene mutation. LMNA mutation was known as a cause of ‘laminopathy’ such as dilated cardiomyopathy, muscular dystrophy, neuropathy and so on. LMNA gene might be a candidate of genetic basis in cryptogenic MGN.

Keywords

Membranous glomerulonephritis Dilated cardiomyopathy Lamin A/C LMNA 

Notes

Acknowledgements

We would like to thank Dr. Kazuaki Kaitani and Dr. Naoaki Onishi, department of cardiology, Japanese Red Cross Otsu Hospital, Japan, for their great contribution. Furthermore, we thank Dr. Yoichiro Kobashi and Mr. Shiomi Yoshida, Tenri Institute of Medical Research, Japan for their help with the histological analyses.

Compliance with ethical standards

Conflict of interest

All the authors have declared that no conflict of interest exists.

Human and animal rights

All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

Informed consent

Informed consent was obtained from the patient for being included in the study.

References

  1. 1.
    Broers JLV, Ramaekers FCS, Bonne G, Yaou RB, Hutchison AC. Nuclear lamins: laminopathies and their role in premature ageing. Physiol Rev. 2006;86:967–1008.CrossRefPubMedGoogle Scholar
  2. 2.
    Kimura T, Kuramochi S, Katayama T, Hoshikawa T, Yamada T, Ueda Y, Okada Y. Amiodarone-related pulmonary mass and unique membranous glomerulonephritis in a patient with valvular heart disease: diagnostic pitfall and new findings. Pathol Int. 2008;58:657–63.CrossRefPubMedGoogle Scholar
  3. 3.
    Beck LH, Bonegio RGB, Lambeau G, Beck DM, Powell DW, Cummins TD, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361:11–21.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Stanescu HC, Arcos-Burgos M, Mediar A, Bockenhauer D, Kottgen A, Dragomirescu L, et al. Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med. 2011;364:616–26.CrossRefPubMedGoogle Scholar
  5. 5.
    Chartier S, Buzzanga JB, Paquin F. Parial lipodystrophy associated with a type 3 form of membranoproliferative glomerulonephritis. J Am Acad Dermatol. 1987;16:201–5.CrossRefPubMedGoogle Scholar
  6. 6.
    Owen KR, Donohoe M, Ellard S, Clarke TJ, Nicholls AJ, Hattersley AT, Bingham C. Mesangiocapillary glomerulonephritis type 2 associated with familial partial lipodystrophy (Dunnigan-Kobberling syndrome). Nephron Clin pract. 2004;96:c35-c38.CrossRefGoogle Scholar
  7. 7.
    Peters DK, Charlesworth JA, Sissons JG, Williams DG, Boulton-Jones JM, Evasn DJ, et al. Mesangiocapillary nephritis, partial lipodystrophy, and hypocomplementaemia. Lancet. 1973;2:535–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Javor ED, Moran SA, Young JR, Cochran EK, Depaoli AM, Oral EA, et al. Proteinuric nephropathy in acquired and congenital generalized lipodystrophy: base line characteristics and course during recombinant leptin therapy. J Clin Endocrinol Metab. 2004;89:3199–207.CrossRefPubMedGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2018

Authors and Affiliations

  1. 1.Department of Diagnostic PathologyTenri HospitalTenriJapan
  2. 2.Department of General MedicineTenri HospitalTenriJapan

Personalised recommendations